ECM
ALNY icon

Everence Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Everence Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$894K Hold
2,970
– – 0.05% 286
2026
Q1 		$983K Hold
2,970
– – 0.06% 240
2025
Q4 		$1.18M Hold
2,970
– – 0.07% 215
2025
Q3 		$1.35M Hold
2,970
– – 0.08% 195
2025
Q2 		$968K Hold
2,970
– – 0.06% 235
2025
Q1 		$802K Buy
2,970
+450
+18% +$116K 0.05% 269
2024
Q4 		$593K Buy
+2,520
New +$663K 0.04% 317

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Everence Capital Management's ALNY Position: Q2 2026 in Review

Everence Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 2,970 shares worth $894K. The position accounts for 0.05% of the portfolio, ranked #286.

Everence Capital Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.35M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Everence Capital Management held 2,970 shares of Alnylam Pharmaceuticals worth $894K as of Q2 2026.
  • Everence Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Everence Capital Management's portfolio in Q2 2026, its #286 holding.
  • Everence Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Everence Capital Management's Alnylam Pharmaceuticals position peaked at $1.35M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.